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ABSTRACT
Introduction and Aims: Osteolytic bone metastases are observed in advanced cases 
of breast cancer. In vitro data suggest that the activity of the calcium-sensing receptor 
(CaSR) expressed by metastatic cells could potentiate their osteolytic potential. This 
study aimed to demonstrate in vivo the involvement of the CaSR in breast cancer cells 
osteolytic potential and to identify potential targets linked to CaSR activity.
Methods and Results: MDA-MB-231 stably transfected with plasmids containing 
either a full-length wild-type CaSR (CaSR-WT), or a functionally inactive dominant 
negative mutant (CaSR-DN) or an empty vector (EV) were intratibially injected 
into Balb/c-Nude mice. X-ray analysis performed 19 days after injection showed a 
dramatic increase of osteolytic lesions in mice injected with CaSR-WT-transfected 
cells as compared to mice injected with EV- or CaSR-DN-transfected cells. This was 
associated with decreased BV/TV ratio and increased tumor burden. Epiregulin, an 
EGF-like ligand, was identiied by a DNA microarray as a possible candidate involved 
in CaSR-mediated osteolysis. Indeed, in vitro, CaSR overexpression increased both 
epiregulin expression and secretion as compared to EV- or CaSR-DN-transfected 
cells. Increased epiregulin expression was also detected in osteolytic bone lesions 
from mice injected with CaSR-WT-transfected MDA-MB-231. In vitro, exposure of 
osteoblastic cells (HOB and SaOS2) to exogenous epiregulin signiicantly decreased 
OPG mRNA expression. Exposure of osteoblastic cells to conditioned media prepared 
from CaSR-WT-transfected cells also decreased OPG expression. This effect was 
partially blocked after addition of an anti-epiregulin antibody.
Conclusions: Overexpression of a functional CaSR in metastatic breast cancer 
cells dramatically ampliies their osteolytic potential through epiregulin-mediated 
OPG downregulation.
INTRODUCTION
Breast cancer is the most common cancer among 
women worldwide. In these patients, metastatic cancer 
is the leading cause of death. Bones are a common place 
for breast cancer cells to metastasize. Within bone tissue, 
breast cancer cells activity favors osteolysis, which 
promotes hypercalcemia [1], bone pain and increases the 
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risk of pathologic fractures. Breast cancer cells and bone 
cells communicate with each other through a vicious 
circle that results in progressive bone destruction and/
or tumour growth [2]. Breast tumors from primary site 
produce parathyroid hormone related peptide (PTHrP) 
[1], which upregulates osteoblasts Receptor Activator of 
NFせB Ligand (RANKL) production. Binding of RANKL 
to its receptor RANK expressed on osteoclast precursor 
cells initiates their maturation and differentiation toward 
activated osteoclasts and stimlates bone resorption [3]. 
The calcium (Ca2+) released from bone resorption is 
thought to locally promote further PTHrP production 
from the metastatic tumour, thereby supporting the 
vicious circle [4]. Growth factors released from bone 
matrix destruction enable tumor cell survival and growth 
in bone microenvironment. This phenomenon ampliies 
the manifestation of bone metastases, which in turn 
increases the rate of bone turnover, thus feeding the 
vicious circle [2].
Initially cloned from parathyroid glands, where it 
is involved in systemic Ca2+ homeostasis [5], the calcium 
sensing receptor (CaSR) recently emerged as a new target 
within this vicious circle. Breast carcinomas express the 
CaSR. Of interest, CaSR expression is higher in breast 
cancer samples from patients with bone metastasis, 
suggesting that CaSR-positive tumors are more likely to 
metastasize to the skeleton [6]. In accordance with this 
hypothesis, expression of the CaSR is higher in breast cancer 
cell lines with relatively increased bone metastatic potential 
such as MDA-MB-231 [6]. Those cells also show a stronger 
CaSR-dependent migratory response to Ca2+ compared 
with cells with a lower metastatic potential (MCF-7, T47D) 
[7]. In malignant breast cells MCF-7 and MDA-MB-231, 
activation of the CaSR by Ca2+ stimulates PTHrP secretion 
[8]. Together, these data suggest that the large amounts of 
Ca2+ released after PTHrP-induced bone resportion could 1/ 
facilitate tumor cell migration into the bone through CaSR 
stimulation and 2/ participate to the vicious circle of bone 
resorption through CaSR induced-PTHrP secretion.
To date, our understanding on how the CaSR is 
involved in the development of osteolytic bone metastasis 
is limited to clinical observations and in vitro experimental 
data. Results obtained from animal models are lacking 
to truly demonstrate these concepts. This study aimed 
to i/ develop a model allowing an in vivo demonstration 
of the involvement of the CaSR on metastatic tumor 
osteolytic potential and to ii/ investigate if CaSR activity 
could inluence osteolysis though a mechanism different 
from PTHrP modulation. For this purpose, we developed 
a model of MDA-MB-231 cells stably transfected to 
overexpress either a wild type or a dominant negative 
(R185Q) form of the CaSR. We demonstrated that the 
overexpression of a functional form of the CaSR favoured 
MDA-MB-231 osteolytic potential when intratibially 
injected to Balb/c-Nude mice. Studies lead by DNA 
microarray identiied epiregulin, as a possible new 
candidate involved in CaSR-mediated osteolysis.
RESULTS
Stable transfection of human MDA-MB-231 
breast cancer cells
To investigate the role of the CaSR on breast cancer 
cells osteolytic potential, we used MDA-MB-231 cells, 
an estrogen-independent breast cancer cell line able to 
colonize bone [9] and to induce osteolytic metastasis [10, 
11]. MDA-MB-231 cells were stably transfected with 
plasmids containing either a full-length wild-type CaSR 
(CaSR-WT) or a functionally inactive dominant negative 
mutant (CaSR-DN). CaSR sequence was FLAG-tagged in 
its C-terminal region to discreminate between endogenous 
and genetically induced CaSR expression. Cells transfected 
with the empty pcDNA3.1/Zeo(+) plasmid (Empty 
Vector (EV)) served as controls. Western blot analyses 
performed with an anti-CaSR antibody demonstrated 
that both CaSR-WT- and CaSR-DN-transfected MDA-
MB-231 displayed increased CaSR expression as 
compared with EV-transfected cells (Figure 1A). The 
same proile of expression was obtained on western 
blots performed with an anti-FLAG antibody (Figure 
1C). Conirming these observations, a signiicant increase 
of both CaSR and FLAG expression was observed with 
low cytometry in CaSR-WT and CaSR-DN-transfected 
MDA-MB-231 as compared with EV-transfected cells 
(Figure 1B and 1D).
Dominant-negative (DN) mutations disrupt the 
activity of wild-type genes [12]. CaSR activation results 
in ERK1/2 pathway activation in various cell types 
[1315], including MDA-MB-231 cells [7]. Thus, we 
investigated CaSR functionality in EV-, CaSR-WT- and 
CaSR-DN-transfected cells through measurement of 
ERK1/2 phosphorylation levels after Ca2+ stimulation. 
Exposure of EV-transfected cells to increasing Ca2+ 
concentrations (from 1.8 to 5.0 mmol/L) promoted 
ERK1/2 phosphorylation in a concentration-dependent 
manner (Figure 1E). These effects were signiicantly 
ampliied in CaSR-WT-transfected cells as compared 
with EV-transfected cells, while CaSR-DN-transfected 
MDA-MB-231 completely lost their abilities to respond 
to Ca2+.
CaSR-WT overexpression enhances MDA-
MB-231 osteolytic potential in vivo
To examine the inluence of CaSR overexpression 
on MDA-MB-231 osteolytic potential, EV-, CaSR-WT- or 
CaSR-DN-transfected cells were intratibially injected into 
Balb/c-Nude mice. The development of bone lesions was 
followed by X-ray up to nineteen days. A sham operated 
mouse was used as a control. Data obtained by radiography 
demonstrated that 19 days after intratibial injection, the 
osteolytic area was around 4 fold wider in mice injected 
with CaSR-WT-transfected cells as compared with mice 
which were injected with EV-transfected cells (Figure 
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2A and 2B). The extent of osteolytic lesions was similar 
between mice injected with EV-transfected MDA-MB-231 
and those injected with CaSR-DN-transfected cells. 
Histomorphometric analysis showed that mice intratibially 
injected with CaSR-WT- transfected MDA-MB-231 
had signiicantly lower BV/TV as compared with mice 
intratibially injected with EV-transfected cells (p=0.0004) 
or CaSR-DN-transfected cells (p=0.02) (Figure 3A and 
3B). There was no signiicant difference between BV/TV 
ratios of mice injected with CaSR-DN-transfected cells 
as compared with mice injected with EV-transfected cells 
(p=0.2). Skeletal tumor burden in the intratibial cavity of 
mice injected with CaSR-WT-transfected cells appeared 
signiicantly more pronounced as compared to mice 
injected with EV- or CaSR-DN-transfected cells, due to 
replacement of bone tissue and bone marrow with tumor 
cells (Figure 3C). No skeletal lesion was observed in the 
sham animals.
Figure 1: Expression and functionality of the CaSR in CaSR-WT-, CaSR-DN- and EV- transfected MDA-MB-231. (A, 
B, C and D) Evaluation of total (A and B) and FLAG-tagged (C and D) CaSR expression in EV-, CaSR-WT- and CaSR-DN-transfected 
MDA-MB-231 performed by western blot (A and C) and low cytometry (B and D). E. Evaluation of ERK1/2 phosphorylation in MDA-
MB-231 transfected with either EV, CaSR-WT or CaSR-DN and exposed for 10 min to increasing [Ca2+
0
] (1.8, 2.5 or 5 mM) (western blot). 
Results represent 3 independent experiments. *p<0.05,**p<0.01 vs. EV. $p<0.05, $$$p<0.001 vs. CaSR-WT cultured in 1.8 mM Ca2+.
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CaSR overexpression is associated with 
increased epiregulin expression in MDA-MB-231 
cells
We hypothesized that the high osteolytic potential 
of CaSR-WT-transfected MDA-MB-231 could be 
the consequence of an altered expression pattern of 
bone-regulatory genes, other than PTHrP. Thus, a 
transcriptomic analysis was performed using RNA 
microarray in order to compare CaSR-WT- and EV-
transfected cells. Out of more than 44000 elements 
assessed, only 34 genes were differentially expressed 
in response to CaSR overexpression: 24 genes were up-
regulated (Supplementary Table 1) and 10 genes were 
down-regulated (Supplementary Table 2). Among them, 
epiregulin (EREG), a known EGF-like ligand, showed a 
Figure 2: CaSR-WT overexpression favours MDA-MB-231 osteolytic potential in vivo. (A) X-ray images of hind limbs taken 
19 days after mice inoculation with EV-, CaSR-WT- or CaSR-DN-transfected MDA-MB-231. Arrow: osteolytic area. (B) Quantiication of 
the osteolytic area. Sham was an age matched animal which had not been injected with tumor cells. ***p<0.001 vs. CaSR-WT.
Figure 3: Intratibial injection of CaSR-WT-transfected MDA-MB-231 lowers BV/TV ratio. (A) Micrographs of Goldners 
trichrome-stained sections of tibial metaphysis. Goldner’s trichrome staining was performed 19 days after intratibial injection. Green: bone 
– Red: bone marrow and tumor cells (asteriks). (B) Bone histomorphometry measurements (BV/TV, bone volume-tissue volume ratio). 
(C) Tumor burden. Sham was an age matched animal which had not been injected with tumor cells. *p<0.05, **p<0.01, ***p<0.001 vs. 
CaSR-WT-transfected cells.
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3 fold up-regulation. Data obtained by quantitative RT-
PCR and immunocytochemistry conirmed that epiregulin 
expression was signiicantly increased in CaSR-WT-
transfected cells as compared with EV- or CaSR-DN-
transfected cells (Figure 4A and 4C). No difference was 
observed between epiregulin transcripts levels from 
EV- and CaSR-DN-transfected cells. ELISA performed 
on supernatants showed increased epiregulin secretion 
in CaSR-WT-transfected cells as compared with EV- or 
CaSR-DN-transfected cells (Figure 4B).
To conirm the link between CaSR activity and 
epiregulin production, CaSR-WT-, CaSR-DN- and EV-
transfected cells were exposed for 24 hours to increasing 
Ca2+ concentrations (1.8, 2.5 and 5 mmol/L) in vitro and 
epiregulin gene expression was assessed by qRT-PCR. In 
our model, Ca2+ signiicantly increased epiregulin gene 
expression in CaSR-WT-transfected MDA-MB-231 in a 
dose dependent manner, with a 4-fold increase observed in 
cells exposed to 5 mmol/L of Ca2+ (Figure 4D). Epiregulin 
expression was not signiicantly modulated in response to 
Figure 4: CaSR activity increases epiregulin expression and secretion by MDA-MB-231 cells in vitro. (A) Evaluation 
of epiregulin (EREG) mRNA expression in either CasR-WT-, CaSR-DN- or EV-transfected cells (qRT-PCR). (B) ELISA performed on 
supernatants from EV-, CaSR-WT- and CaSR-DN-transfected MDA-MB-231 to detect epiregulin secretion. **p<0.01 or ***p<0.001 vs. 
CaSR-WT. (C) Immunocychemical evaluation of epiregulin protein expression in EV-, CaSR-DN or CaSR-WT MDA-MB-231. Scale bars: 
50 たm. (D) Evaluation of epiregulin (EREG) mRNA expression in CasR-WT-, CaSR-DN- and EV-transfected cells exposed for 24 hours to 
1.8, 2.5 or 5 mM of Ca2+. $p<0.05 or $$p<0.01 vs. cells exposed to 5 mM Ca2+. Results represent 3 independent experiments.
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Ca2+ neither in EV-, nor in CaSR-DN-transfected MDA-
MB-231.
Data obtained by immunohistochemistry 
demonstrated an increased epiregulin expression within 
osteolytic bone lesions from mice injected with CaSR-
WT-transfected MDA-MB-231 compared with bones from 
mice injected with either EV- or CaSR-DN-transfected 
cells (Figure 5).
Epiregulin decreases OPG but not RANKL 
expression in human osteoblastic cells
EGF-like ligands were recently reported to promote 
osteoclastogenesis by decreasing OPG expression 
in osteoblastic cells, without modulation of RANKL 
expression [16]. We thus studied the effects of epiregulin 
on the RANKL/OPG ratio in two types of osteoblastic 
cells: the human osteoblastic cell line SaOS2 and the 
primary human osteoblastic cells HOB. Data obtained 
by qRT-PCR demonstrated that exposure of both 
SaOS2 and HOB cells to increasing concentrations of 
exogenous epiregulin decreased OPG gene expression in 
a concentration dependent manner (Figure 6A and 6B), 
without modulation of RANKL expression (Figure 6C and 
6D).
To ascertain that CaSR activation in tumor cells is 
responsible for decreased osteoblasts OPG production, 
SaOS2 and HOB cells were exposed for 24 hours to 
conditioned media prepared from CaSR-WT-, CaSR-DN- 
and EV-transfected cells exposed to 5 mmol/L of Ca2+ 
for 24 hours. Exposure of SaOS2 and HOB cultures to 
conditioned media prepared from CaSR-WT-transfected 
cells decreased OPG mRNA expression by approximately 
50% as compared with EV- and CaSR-DN-transfected 
cells (Figure 7A and 7B). Exposure to conditioned media 
prepared from CaSR-DN and EV-transfected cells had no 
effect on HOB and SaOS2 OPG expression as compared 
with the control condition.
To evaluate if the decrease of OPG expression 
induced by conditioned medial from CaSR-WT-transfected 
Figure 5: Epiregulin expression is increased in osteolytic bone lesions from mice injected with CaSR-WT-transfected 
MDA-MB-231. Immunohistochemical evaluation of epiregulin protein expression in bone sections from mice injected with EV-, CaSR-
DN- or CaSR-WT-MDA-MB-231. BM: bone marrow, TB: trabecular bone, Asterisk: positive staining for epiregulin within invaded 
osteolytic bone lesions. Scale bars: 100 たm.
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cells depends on epiregulin secretion, the same procedure 
was reproduced using a neutralizing antibody targeting 
epiregulin. As demonstrated in Figure 7C and 7D, the 
use of the anti-epiregulin antibody partially blocked the 
decrease of OPG expression observed in response to a 24 
hours exposure to conditioned media from CaSR-WT-
transfected cells, in both SaOS2 and HOB cells.
DISCUSSION
This report demonstrated that high expression of 
a functional CaSR conferred osteolytic advantage to 
MDA-MB-231 cells when intratibially injected to Balb/c-
Nude mice in vivo. It also provided evidence that CaSR 
activation in MDA-MB-231 cells promoted the expression 
and secretion of epiregulin, an EGF-like ligand, which 
decreased OPG expression in osteoblastic cells.
Stable transfection of MDA-MB-231 cells with 
plasmids containing either a full-length functional 
wild-type CaSR (CaSR-WT) or a functionally inactive 
dominant negative mutant (CaSR-DN) or an empty 
vector, and their subsequent intratibial injection into 
Balb/c-Nude mice allowed us to create an accurate model 
to study the involvment of the CaSR in metastatic bone 
osteolysis. A dramatical osteolysis had been observed 
after injection with MDA-MB-231 transfected to 
overexpress a functional CaSR (CaSR-WT) as compared 
with mice injected with EV- and CaSR-DN-transfected 
cells. This suggests that a high level of functional CaSR 
may be necessary for metastatic breast cancer cells to 
promote bone osteolysis. These data support observations 
from Mihai et al., who reported that high tumor CaSR 
expression strongly associates with the presence of bone 
metastases [6]. Of note, skeletal tumor burden was more 
Figure 6: Epiregulin decreases OPG but not RANKL expression in osteoblastic cells SaOS2 and HOB. (A, B, C and D) 
Evaluation of osteoprotegerin (OPG) (A and B) and RANKL (C and D) mRNA expression in SaOS2 (A and C) and HOB (B and D) cells 
exposed for 24 hours to recombinant epiregulin (qRT-PCR). **p<0.01 or ***p<0.001 vs control condition (without epiregulin). $p<0.05 or 
$$p<0.01 vs. cells exposed to 1ng/mL of epiregulin. Results represent 3 independent experiments.
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pronounced within the intratibial cavity of mice injected 
with CaSR-WT-transfected cells than in mice injected with 
EV- or CaSR-DN-transfected cells. This was associated 
with increased expression of Ki67, a cellular marker of 
proliferation, within osteolytic lesions from mice injected 
with CaSR-WT-transfected cells (Supplementary Figure 
1). This suggests that the high amounts of Ca2+ released 
at sites of bone resorption might promote CaSR-induced 
MDA-MB-231 cell proliferation. However, data obtained 
in vitro showed that Ca2+-induced CaSR activation did not 
modulate neither the proliferation, nor the apoptosis of 
EV-, CaSR-DN- or CaSR-WT-transfected MDA-MB-231 
cells (Supplementary Figure 2A and 2B.). To explain 
this phenomenon, we hypothesized that the osteolysis 
induced in vivo by the MDA-MB-231 overexpressing the 
functional CaSR might have favored the release of growth 
factors such as TGF-く from the bone matrix, which in turn 
might have favored tumor cell proliferation.
In vitro, activation of the CaSR with Ca2+, 
spermine, aminoglycoside antibiotics or allosteric (type 
II) calcimimetics increased PTHrP secretion by breast 
cancer cells [8, 17]. Since PTHrP secretion by metastatic 
cells increases osteoblasts RANKL production and 
subsequent osteclastogenesis, the current prevailing view 
is that CaSR osteolytic potential comes from its ability to 
increase metastatic breast cancer cells PTHrP secretion. We 
hypothesized that, apart from PTHrP secretion, high CaSR 
activity might modulate the expression pattern of other 
bone regulatory genes. Data obtained from comparative 
transcriptomic analysis identiied epiregulin, which 
expression is tripled in CaSR-WT-transfected MDA-MB-31 
as compared to EV-transfected cells, as a potential candidate.
Figure 7: CaSR-mediated epiregulin secretion by MDA-MB-231 decreases OPG expression in osteoblastic cells.  
(A and B) Evaluation of OPG mRNA expression in SaOS2 (A) and HOB (B) cells exposed for 24 hours to conditioned media (CM) 
prepared after exposure of CaSR-WT-, CaSR-DN- or EV-transfected MDA-MB-231 to 5 mM of Ca2+
0
 (qRT-PCR). *p<0.05 vs control 
condition (CT : 5 mM of Ca2+
0
). $p<0.05 or $$p<0.01 vs. CM from CaSR-WT-transfected cells. (C and D) Evaluation of OPG mRNA 
expression in SaOS2 (C) and HOB (D) cells exposed for 24 hours to CM from CaSR-WT-transfected MDA-MB-231, with or without 
anti-epiregulin antibody (qRT-PCR). *p<0.05 vs untreated cells. $p<0.05 vs. CM from CaSR-WT-transfected cells without anti-epiregulin 
antibody. Results represent 3 independent experiments performed in triplicate.
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Epiregulin belongs to the epidermal growth factor 
(EGF) family of peptide growth factors [18]. EGF-
like ligands and their cognate receptors modulate cell 
functions in a variety of ways, including proliferation, 
survival, adhesion, migration and differentiation. In this 
work, data obtained in vitro conirmed that epiregulin 
expression and secretion were highly upregulated in 
CaSR-WT-transfected cells compared to CaSR-DN- or 
EV-transfected cells. This was associated with increased 
epiregulin detection in osteolytic lesions from mice 
intratibially injected with CaSR-WT-transfected MDA-
MB-231 compared to mice injected with CaSR-DN- or 
EV- transfected cells. This phenomenon may result both 
from the high level of epiregulin expressed in CaSR-WT-
transfected cells and the increased tumor burden observed 
in response to high CaSR activity. Conirming the link 
between CaSR activity and epiregulin gene expression, 
Ca2+ stimulation of the functional CaSR overexpressed in 
MDA-MB-231 cells concentration-dependently increased 
epiregulin mRNA expression while no difference was 
seen neither in EV-, nor in CaSR-DN-transfected MDA-
MB-231.
In a recent study, Zhu et al. reported that EGF-
like ligands strongly stimulate osteoclast formation 
in co-cultures of osteoblastic cells and bone marrow 
macrophages (BMMs) through the down-regulation 
of osteoblast OPG and MCP-1 [16]. In this study, co-
cultures with MDA-MB-231 had similar effects on 
osteoblasts expression of OPG and MCP-1. Those effects 
could be partially abolished by EGFR inhibitor. Thus, 
the authors reasoned that EGF-like ligands, similarly to 
PTHrP, may increase osteolytic lesions [16]. In our model, 
overexpression of a functional CaSR ampliies MDA-
MB-231 osteolytic potential and epiregulin secretion in 
vivo. We thus hypothesized that CaSR effects on MDA-
MB-231 osteolytic potential could be the consequence 
of decreased osteoblasts OPG expression in response to 
increased epiregulin secretion by metastatic cells.
In line with this hypothesis, exposure of both 
HOB and SaOS2 cells to increasing doses of epiregulin 
decreased OPG gene expression in a concentration 
dependent manner. Conirming previous data obtained 
from Zhu et al. [16] we did not observe any modulation of 
osteoblasts RANKL expression in response to exogenous 
epiregulin. Conditioned media prepared from CaSR-WT-
transfected cells decreased both SaOS2 and HOB OPG 
mRNA expression by approximately 50% as compared 
with EV- and CaSR-DN-transfected cells. The use of a 
neutralizing antibody targeting epiregulin partially blocked 
this phenomenon, demonstrating that CaSR-mediated 
decrease of OPG in osteoblastic cells partly depends on 
epiregulin secretion. Since CaSR activation on tumor cells 
promotes the secretion of PTHrP, which is also known to 
block OPG production [3], the fact that the neutralizing 
antibody targeting epiregulin does not totally block CaSR-
mediated decrease in OPG expression is not surprising. 
In prostate cancer cells, CaSR stimulation transactivates 
the EGFR, leading to ERK phosphorylation and resultant 
PTHrP secretion [19]. Based on this observation, 
we cannot exclude in our study that CaSR-mediated 
Figure 8: Involvement of the CaSR-epiregulin axis on the vicious circle of bone metastasis-induced osteolysis. At sites of 
bone resorption, the high amounts of Ca2+
0
 released (1) can activate the CaSR expressed by breast cancer-derived metastatic cells (2), which 
promotes epiregulin synthesis (3) and secretion (4). Epiregulin ixation on its receptors expressed by osteoblasts inhibits OPG synthesis (5), 
thus favoring interactions between RankL expressed by osteoblasts and its receptor RANK expressed by immature osteoclasts. This favors 
osteoclastogenesis and in turn increases the rate of bone turnover, thus feeding the vicious circle.
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epiregulin secretion might locally transactivate EGFR and 
improve PTHrP secretion by MDA-MB-231, which would 
indirectly worsen OPG inhibition in osteoblasts.
It would have been interesting to assess variations 
in osteoclasts number as a consequence of CaSR-
induced osteolysis. However, in our model, the osteolytic 
activity of CaSR-WT-transfected MDA-MB-231 was so 
strong within 19 days, that the tumor invaded almost the 
whole bone. Therefore, there were almost no bone, and 
consequently no bone cells, left within those lesions. This 
would have biased the assessment of osteoclasts number.
To conclude, our data revealed an important role 
for the CaSR-epiregulin axis on metastatic breast cancer 
cells osteolytic potential. At site of bone resorption (Figure 
8), the activation by Ca2+ of the CaSR expressed by 
metastatic breast cancer cells favors epiregulin synthesis 
and secretion, which in turn acts on osteoblastic cells to 
reduce OPG synthesis. By reducing the level of OPG 
released in bone microenvironment, the CaSR-epiregulin 
axis might increase bone resorption through increased 
osteoclastogenesis. EGFR inhibitors, such as cetuximab 
(which targets the receptor itself) or geitinib and erlotinib 
(which target EGFR tyrosine kinase), were recently shown 
to eficiently reduce osteolytic lesions promoted in vivo 
by ADAMTS1 and MMP1 overexpressing MDA-MB-231, 
which secretes high amount of EGF like ligand. In line 
with this statement, signiicant relief of bone pain was 
observed in patients with bone metastasis in a clinical trial 
of the EGFR tyrosine kinase inhibitor. Together with these 
data, our work sheds lights on EGFR inhibitors as possible 
therapeutic strategies to prevent CaSR-mediated osteolytic 
bone metastasis.
MATERIALS AND METHODS
Cell lines and stable transfections
CaSR-WT and CaSR-DN cDNAs (CaSR R185Q) 
which have been described previously were used for the 
transfection of MDA-MB-231 cells (ATCC® HTB-26TM) 
[20]. The coding regions of CaSR-WT and CaSR-DN 
containing a FLAG-tagged sequence were ampliied by 
polymerase chain reaction (PCR) and subcloned at the 
HindIII/XbaI sites of the pcDNA3.1/Zeo(+) vector (V860-
20, Invitrogen). MDA-MB-231 were transfected with 
pcDNA3.1/Zeo(+) vector containing CaSR-WT cDNA 
or CaSR-DN cDNA using Lipofectamine 2000 (catalog 
#11668-027, Invitrogen). MDA-MB-231 transfected 
with the empty vector (EV) were used as controls. Stably 
transfected cells were selected by growing them in zeocin-
containing medium and cloned by limiting dilution. These 
cells were then routinely cultured in MEM (catalog 
#M4526, Sigma, St Louis, MO) supplemented with 10% 
fetal bovine serum (FBS), 1% GlutaMax, 1% of Penicillin-
Streptomycin (complete MEM) and 0.8 mg/mL zeocin 
(catalog # R25005, Invitrogen). For the study of MAPK 
ERK activation, stably transfected MDA-MB-231 (150 
000 cells/well; 6-well plates) were starved for 4 hours and 
stimulated for 10 minutes with increasing concentrations 
of Ca2+ (1.8, 3.0 or 5.0 mmol/L). Conditioned media (CM) 
mentioned in the manuscript were prepared by exposure of 
EV-, CaSR-WT- or CaSR-DN-transfected MDA-MB-231 
to 5 mmol/L of Ca2+ for 24 hours.
The cell line of human osteosarcoma (SaOS2) was 
purchased from ATCC (ATCC® HTB-85TM) and routinely 
cultured in complete DMEM (catalog #M5677, Sigma, 
St Louis, MO). Primary cultures of human osteoblasts 
(HOB) were purchased from Promocell (catalog #C-
12720, Heidelberg, Germany) and cultured in Osteoblast 
Growth Medium (catalog # C-27001, Promocell, 
Heidelberg, Germany).
Western blot analysis
Briely, cells were washed once with PBS and 
homogenized at 4°C in a lysis buffer (10mM Tris-HCl, 
150 mM NaCl, 10% glycerol, 2 mM Na3VO4 and 
protease inhibitors pH 7.4) containing either 1% NP40 (for 
the study of p42/44 proteins) or 1% SDS (for the study 
of CaSR expression). Proteins were then separated in 8 
or 10% SDS-PAGE. After electrophoresis, samples were 
transferred to nitrocellulose membranes, blocked with 
5% skimmed milk in TBS/0.1% v/v Tween 20 for 1 h, 
washed with TBS/Tween and incubated overnight at 4°C 
with primary antibodies : mouse monoclonal anti-CaSR 
(1:5000) (catalog #NB120-19347, Novus Biologicals), 
mouse monoclonal anti-FLAG M2 (1:2000) (catalog 
#200471, Agilent Technologies), rabbit polyclonal anti-
phospho-ERK1/2 (1:1000) and rabbit polyclonal anti-
ERK1/2 (1:1000) (catalog #9101 and #9102 respectively, 
Cell Signaling, Danvers, MA). Antibodies were diluted in 
5% milk TBS/Tween. Blots were washed with TBS/Tween 
and incubated with appropriate horseradish peroxidase-
conjugated secondary antibody (1:5000) (catalog #sc-2005 
and #sc-2004 for anti-mouse and anti-rabbit respectively, 
Santa Cruz Biotechnology). After washing with TBS/
Tween, blots were developed with the chemiluminescence 
method (ECL) (catalog #RPN2232, Amersham, Aylesbury, 
UK) and then probed with mouse monoclonal anti-く-actin 
antibody (1:2000) (catalog # A1978, Sigma, St Louis, 
MO) following the same method and levels of expression 
were corrected for minor differences in loading.
Flow cytometry analysis
MDA-MB-231 were detached using cell 
dissociation solution (catalog # C5914, Sigma, St Louis, 
MO) and permeabilized using the Cytoix/CytopermTM 
Plus ixation/permeabilization kit (catalog #554715, 
BD Biosciences, Le Pont de Claix, France) following 
manufacturers instructions. Cells were then incubated for 
1 h at 4°C with primary antibody (mouse mAb anti-CaSR 
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(5C10, ADD), catalog # ab19347, Abcam, 1:40 dilution 
from original unit); or mouse monoclonal anti-FLAG 
M2 (1:100) (catalog #200471, Agilent Technologies) 
or control isotype (catalog #X0943, Dako-Cytomation, 
Glostrup, Denmark), then washed in PBS containing 
0.5% BSA, and labelled using polyclonal goat anti-
mouse immunoglobulins/RPE (catalog # R0480, Dako-
Cytomation, Glostrup, Denmark 1:50 dilution). Protein 
expression was assessed by low cytometry using FACS 
CantoII (BD Biosciences, Le Pont de Claix, France). The 
results are presented in per cent of control condition (EV).
Microarrays analysis
Total RNA from EV- and CaSR-WT-transfected 
MDA-MB-231 cells were isolated using RNeasy Mini 
Kit (catalog #74106, Qiagen France, Courtaboeuf). 
After treatment with turbo DNase (Life technologies, 
Illkirch, France), the quality of RNA samples was tested 
using RNA 6000 Nano kit and analyzed with Agilent 
2100 Bioanalyser. Microarrays analysis was performed 
by PEGASE Biosciences (France) from Agilent Whole 
Human Genome 4x44K arrays.
ELISA for epiregulin
Quantitative detection of soluble epiregulin was 
performed from supernatants of EV-, CaSR-WT- or CaSR-
DN-transfected MDA-MB-231 using a commercially 
available kit (SEB945Hu 96 Tests, Cloud-Clone Corp.) 
according to manufacturer's instructions.
Quantitative reverse transcription PCR  
(qRT-PCR)
Total RNA was extracted from EV-, CaSR-WT- or 
CaSR-DN-transfected MDA-MB-231 using the RNeasy 
Mini Kit (catalog #74106, Qiagen France, Courtaboeuf). 
RNA was reverse transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription Kit” (catalog 
#4368813, Applied Biosystems, Foster City, CA, USA) 
according to manufacturer's instructions. The qRT-PCR 
was performed on StepOnePlus real time PCR system 
(Applied Biosystems, Foster City, CA, USA) using gene-
speciic primers for epiregulin (catalog #QT00019194), 
OPG (catalog # QT00014294) or RANK-L (catalog # 
QT00215614) (QuantiTect Primer Assay, Qiagen France, 
Courtaboeuf). RNA expression of the different genes 
was corrected for GAPDH using the following primers: 
forward 5_atcaccatcttccaggagcga_3 and reverse 5_
agccttctccatggtggtgaa_3.
Animal studies
All procedures, including housing and care 
of the mice, euthanasia, and experimental protocols 
were conducted in accordance with a code of practice 
established by the local ethical committee of the 
University of Lyon (Lyon, France). This study was 
monitored on a routine basis by a veterinarian to ensure 
continued compliance with the proposed protocols.
Five-weeks-old female BALB/c homozygous (nu/
nu) athymic mice were purchased from Charles River 
(Saint Germain sur l'Arbresle, France) and distributed 
in 3 groups (7 animals/group, plus a sham-operated 
mouse). After one week of acclimation, the mice were 
anesthetized by intraperitoneal injection of a solution (20 
たl/g) containing 0,5 mg/mL of ketamine and 8 mg/mL of 
xylazin in saline solution (NaCl 0,9%) and received an 
intratibial injection of 100000 cells (EV, CaSR-WT and 
CaSR-DN) into the right hind limb. A Sham operated 
mouse was used as a control.
On days 7, 14 and 19 after tumor cell inoculation, 
radiographs of anesthetized mice were taken with the use 
of MIN-R2000 ilm (Kodak, Rochester NY) in an MX-
20 cabinet X-ray system (Faxitron X-ray Corp, Wheeling, 
IL). Osteolytic lesions were identiied on radiographs as 
radiolucent lesions in the bone. The area of the osteolytic 
lesions was measured using a Visiolab2000 computerized 
image analysis system (Explora Nova) and the extent 
of bone destruction per animal was expressed in square 
millimeters. Anesthetized mice were sacriiced after 
radiography on day 19 after tumor cell inoculation.
Bone histomorphometry and histology
Besides radiography, tumor growth and osteolytic 
lesions were analyzed by histology. For this purpose, 
tibiae from animals were ixed, decalciied with 15% 
EDTA/ 0.4% PFA and embedded in parafin. Section of 
6-たm were stained with Goldner’s Trichrome and used 
for histologic and histomorphometric analyses by means 
of a computerized image analysis system (Visiolab 2000). 
Histomorphometric measurements (i.e. bone volume to 
tissue volume [BV/TV] ratios) were performed in a standard 
zone of the tibial metaphysis, situated at 0.5 mm from the 
growth plate, including cortical and trabecular bones. The 
BV/TV ratio represents the percentage of bone tissue.
Immunohistochemistry for epiregulin
Section of 6-たm were deparafinized and incubated 
in sodium citrate (1M, pH=6) during 20 min at 100°C for 
antigen retrieval. Section were then ixed with 4% ice-cold 
paraformaldehyde (PFA) for 5 min at room temperature 
(RT), and quenched in 100 mmol/L glycin/PBS for 
additional 10 min. Tissues were then permeabilized for 10 
min at RT with 0.1% triton X-100 in PBS containing 1% 
BSA. Non-speciic binding of the antibody was blocked by 
incubation in a blocking solution (1% BSA in PBS) for 30 
min at RT. Sections were then incubated overnight at 4°C 
with primary antibody (goat polyclonal IgG anti-epiregulin, 
R&D Systems, AF1195, 1:50 dilution from original unit) 
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prepared in PBS containing 1% BSA. Bone sections 
were then rinsed and incubated with secondary antibody 
(AlexaFluor®488 Donkey anti-goat IgG Invitrogen 
A11055, 1:500 dilution from original unit), prepared in PBS 
1% BSA, for 1 hr at RT. Samples were then widely washed 
in PBS. Nuclei were then counterstained with Hoechst and 
slides were mounted in Mowiol solution (Calbiochem®, 
Mowiol® 4-88) for luorescent detection. The same 
protocol was performed to detect epiregulin expression on 
MDA-MB-231 monolayers on coverslips, except that the 
step of sodium citrate antigen retrieval was skipped.
Statistical analysis
StatView v5.0 (version 5.0; SAS Institute, Inc.) 
was used for statistical analysis. Normally distributed 
data are presented as means ± Standard Error of the Mean 
(SEM) and non-normally distributed data as medians and 
minimum and maximum values. Kruskal Wallis test was 
used to compare the three groups for in vivo experiments. 
To account for multiple testing, Dunns multiple 
comparison test was performed. All statistical tests were 
two-sided. For qRT-PCR and ELISA test results, a one-
way ANOVA test was used to evaluate if differences 
between group means were statistically signiicant. P 
values of <0.05 were considered statistically signiicant.
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length wild-type CaSR,; CaSR-DN : functionally inactive 
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